Toward standardization of cardiac troponin I measurements part II: Assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays

被引:72
作者
Christenson, Robert H.
Duh, Show Hong
Apple, Fred S.
Bodor, Geza S.
Bunk, David M.
Panteghini, Mauro
Welch, Michael J.
Wu, Alan H. B.
Kahn, Stephen E.
机构
[1] Univ Maryland, Med Ctr, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
[2] Hennepin Cty Med Ctr, Dept Lab Med & Pathol, Minneapolis, MN 55415 USA
[3] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
[4] Denver Hlth Med Ctr, Denver, CO USA
[5] NIST, Analyt Chem Div, Gaithersburg, MD 20899 USA
[6] Univ Milan, Dipartimento Sci Clin Luigi Sacco, Milan, Italy
[7] Univ Calif San Francisco, Dept Pathol & Lab Med, San Francisco, CA 94143 USA
[8] Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA
[9] Loyola Univ, Med Ctr, Dept Cell Biol, Maywood, IL 60153 USA
[10] Loyola Univ, Med Ctr, Dept Neurobiol & Anat, Maywood, IL 60153 USA
关键词
D O I
10.1373/clinchem.2006.068437
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Cardiac tropoin I (cTnI) measurements show an similar to 20- to 40-fold difference between assays, and better standardization and harmonization are needed. Toward this goal, the AACC cTnI Standardization Committee collaborated with the National Institute of Standards and Technology (NIST) in an earlier study to select 2 candidate reference materials (cRMs). Methods: Two troponin cRMs, a troponin C-troponin I-troponin T (CIT) complex from human heart tissue and a CIT complex from recombinant technology, were supplied to NIST for assessment of composition and purity, and cTnI value assignment. These cRMs and 6 cTnI-positive human serum pools were shipped to manufacturers of 15 cTnI assays. Commutability of the materials was examined by determining the numerical relationship for the cRM preparations between each manufacturer-specified field method and each of the other 14 field methods. These relationships were then compared with the corresponding numerical relationships for the human serum pools. Harmonization of methods was accomplished by determining regression parameters relative to the analytical system yielding values closest to the median for each serum pool. These regression parameters were used to recalculate pool values to harmonize the assays. Interassay CVs before and after harmonization were determined. Results: Characterization of the CIT and CI cRMs showed that these materials were of specified composition. The proportion of cTnI methods that demonstrated commutability for the CIT cRM was 45%; for the CI cRM, 39% of methods demonstrated commutability. Interassay cTnI variability for the field methods ranged from 82% to 97%, median 88%. After harmonization, variability of the serum pools for the cTnI methods was decreased to between 9.0% and 23%, median 15.5%. Conclusions: The proportion of methods demonstrating commutability was too low for use as a common calibrator for the cTnI field methods. However a simple strategy using serum pools can improve harmonization of field cTnI methods by more than 5-fold. The CIT cRM was selected by the AACC cTnI standardization committee, and a new lot has been classified as the cTnI certified reference material Standard Reference Material 2921 by NIST. (c) 2006 American Association for Clinical Chemistry
引用
收藏
页码:1685 / 1692
页数:8
相关论文
共 25 条
[1]   Myocardial infarction redefined -: A consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Alto, P ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
Van de Werf, F ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) :959-969
[2]   Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes:: a meta-analysis of all major randomised clinical trials [J].
Boersma, E ;
Harrington, RA ;
Moliterno, DJ ;
White, H ;
Théroux, P ;
Van de Werf, F ;
de Torbal, A ;
Armstrong, PW ;
Wallentin, LC ;
Wilcox, RG ;
Simes, J ;
Califf, RM ;
Topol, EJ ;
Simoons, ML .
LANCET, 2002, 359 (9302) :189-198
[3]   ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-Segment elevation myocardial infarction - Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) [J].
Braunwald, E ;
Antman, EM ;
Beasley, JW ;
Califf, RM ;
Cheitlin, MD ;
Hochman, JS ;
Jones, RH ;
Kereiakes, D ;
Kupersmith, J ;
Levin, TN ;
Pepine, CJ ;
Schaeffer, JW ;
Smith, EE ;
Steward, DE ;
Theroux, P ;
Gibbons, RJ ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Hiratzka, LF ;
Jacobs, AK ;
Smith, SC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (07) :1366-1374
[4]   Heterogeneity in human cardiac troponin I standards [J].
Bunk, DM ;
Dalluge, JJ ;
Welch, MJ .
ANALYTICAL BIOCHEMISTRY, 2000, 284 (02) :191-200
[5]   Characterization of a new certified reference material for human Cardiac Troponin I [J].
Bunk, DM ;
Welch, MJ .
CLINICAL CHEMISTRY, 2006, 52 (02) :212-219
[6]  
Christenson RH, 2001, CLIN CHEM, V47, P431
[7]  
Christenson RH, 1999, CLIN CHEM, V45, P1414
[8]   Intermethod variation in serum carcinoembryonic antigen (CEA) measurement. Fresh serum pools and control materials compared [J].
Dominici, R ;
Cabrini, E ;
Cattozzo, G ;
Ceriotti, F ;
Grazioli, V ;
Scapellato, L ;
Franzini, C .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (02) :167-173
[9]  
Franzini C, 1993, J Int Fed Clin Chem, V5, P169
[10]   Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels [J].
Hamm, CW ;
Heeschen, C ;
Goldmann, B ;
Vahanian, A ;
Adgey, J ;
Miguel, CM ;
Rutsch, W ;
Berger, J ;
Kootstra, J ;
Simoons, ML .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (21) :1623-1629